Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of AIDS-defining events among advanced naïve patients after HAART.
Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Pietro MD, Migliorino G, Quiros-Roldan E, Ladisa N, Sighinolfi L, Gatti F, Carosi G; Italian MASTER Cohort. Torti C, et al. Among authors: gatti f. HIV Clin Trials. 2007 May-Jun;8(3):112-20. doi: 10.1310/hct0803-112. HIV Clin Trials. 2007. PMID: 17621458
HIV-related liver disease: ARV drugs, coinfection, and other risk factors.
Puoti M, Nasta P, Gatti F, Matti A, Prestini K, Biasi L, Carosi G. Puoti M, et al. Among authors: gatti f. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb;8(1):30-42. doi: 10.1177/1545109708330906. Epub 2009 Feb 11. J Int Assoc Physicians AIDS Care (Chic). 2009. PMID: 19211929 Review.
The impact of gender and anchor drugs on TDF renal toxicity.
Quiros-Roldan E, Amadasi S, Paraninfo G, Izzo I, Allegri R, Motta D, Gatti F, Cristini G, Carosi G, Mendeni M, Torti C. Quiros-Roldan E, et al. Among authors: gatti f. J Acquir Immune Defic Syndr. 2010 Oct;55(2):e11-2. doi: 10.1097/QAI.0b013e3181ef7930. J Acquir Immune Defic Syndr. 2010. PMID: 20859083 No abstract available.
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, Ellinghaus D, Khan A, Martínez-Bueno M, Rolker S, Amitrano S, Roade Tato L, Fava F; FinnGen; COVID-19 Host Genetics Initiative (HGI); Spinner CD, Prati D, Bernardo D, Garcia F, Darcis G, Fernández-Cadenas I, Holter JC, Banales JM, Frithiof R, Kiryluk K, Duga S, Asselta R, Pereira AC, Romero-Gómez M, Nafría-Jiménez B, Hov JR, Migeotte I, Renieri A, Planas AM, Ludwig KU, Buti M, Rahmouni S, Alarcón-Riquelme ME, Schulte EC, Franke A, Karlsen TH, Valenti L, Zeberg H, Richards JB, Ganna A. Nakanishi T, et al. J Clin Invest. 2021 Dec 1;131(23):e152386. doi: 10.1172/JCI152386. J Clin Invest. 2021. PMID: 34597274 Free PMC article. Clinical Trial.
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.
Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Montano M, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. Nicastri E, et al. Among authors: gatti f. J Clin Microbiol. 2003 Jul;41(7):3007-12. doi: 10.1128/JCM.41.7.3007-3012.2003. J Clin Microbiol. 2003. PMID: 12843034 Free PMC article. Clinical Trial.
338 results